Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674754 | 1.00 | MAOB (0.47) | MAOBDAOHCAR2FFAR1FFAR4 | |
| SCHEMBL7249773 | 0.94 | MAOB (0.46) | MAOB | |
| SCHEMBL15923189 | 0.93 | PRSS1 (0.47) | MAOB | |
| SCHEMBL9774681 | 0.93 | PRSS1 (0.47) | MAOB | |
| SCHEMBL30044154 | 0.90 | MAOB (0.49) | MAOBDAOHCAR2MAOA | |
| SCHEMBL1497882 | 0.90 | MAOB (0.49) | MAOBDAOHCAR2MAOA | |
| SCHEMBL5317195 | 0.90 | DRD2 (0.50) | FFAR1 | |
| SCHEMBL17911614 | 0.86 | KCNA3 (0.48) | MAOBMAOA | |
| SCHEMBL5659153 | 0.82 | MAOB (0.45) | MAOBDAOHCAR2FFAR1FFAR4 | |
| SCHEMBL3290620 | 0.81 | FFAR1 (0.47) | MAOBDAOFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388581-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12331052-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3897621-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132605-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2570128-B1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| EP-2828238-B1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP ZOO (PL) | 2016-05-25 | — | — | EP | disclosed |
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9144571-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150238470-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1740177-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005123748-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005104745-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | MAOB 411/4885DAO 1016/4885HCAR2 107/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | MAOB 43/4885DAO 926/4885HCAR2 1333/4885 |
| US-20250388581-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | MAOB 85/4885DAO 356/4885HCAR2 290/4885 |
| US-12331052-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | MAOB 76/4885DAO 743/4885HCAR2 216/4885 |
| US-20150238470-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | MAOB 411/4885DAO 1016/4885HCAR2 107/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | MAOB 130/4885DAO 824/4885HCAR2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.